Solid Lipid Nanoparticles for Efficient Oral Delivery of Tyrosine Kinase Inhibitors: A Nano Targeted Cancer Drug Delivery
Open Access
- 3 July 2021
- journal article
- review article
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 12 (2) , 298-308
Abstract
Tyrosine kinase inhibitors (TKIs) are used as targeted therapy for cancer by inhibiting the signaling pathway and tumor growth. Many TKIs got approved by FDA in recent times for the treatment of cancer by oral route. However, the TKIs have formulation challenges leading to compromised bioavailability which can cause a weak therapeutic response. The cancer nanotherapeutics using nanocarriers based drug delivery has emerged as an advanced tool to provide a solution to formulation challenges and a better cancer therapy by overcoming the limitations in conventional cancer therapy. This review describes the various formulation issues of anticancer drugs with a special reference to TKIs, as well as the capability of solid lipid nanoparticles for an efficient nano targeted cancer drug delivery.Keywords
This publication has 66 references indexed in Scilit:
- Pharmaceutical nanotechnology for oral delivery of anticancer drugsAdvanced Drug Delivery Reviews, 2013
- Clinical Pharmacokinetics of Tyrosine Kinase InhibitorsClinical Pharmacokinetics, 2011
- Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticlesAdvanced Drug Delivery Reviews, 2011
- Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral DrugsThe AAPS Journal, 2009
- Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic deliveryNanomedicine: Nanotechnology, Biology and Medicine, 2009
- Effects of Food on the Relative Bioavailability of Lapatinib in Cancer PatientsJournal of Clinical Oncology, 2009
- Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individualsAnti-Cancer Drugs, 2008
- Overview of the changing paradigm in cancer treatment: Oral chemotherapyAmerican Journal of Health-System Pharmacy, 2007
- Functional interaction of intestinal CYP3A4 and P‐glycoproteinFundamental & Clinical Pharmacology, 2004
- Molecular Properties That Influence the Oral Bioavailability of Drug CandidatesJournal of Medicinal Chemistry, 2002